J Membr Biol, 2024, 258(1):29-46

Sphingomyelin Inhibits Hydrolytic Activity of Heterodimeric PLA2 in Model Myelin Membranes: Pharmacological Relevance

In this work, the heterodimeric phospholipase A, HDP-2, from viper venom was investigated for its hydrolytic activity in model myelin membranes as well as for its effects on intermembrane exchange of phospholipids (studied by phosphorescence quenching) and on phospholipid polymorphism (studied by H-NMR spectroscopy) to understand the role of sphingomyelin (SM) in the demyelination of nerve fibers. By using well-validated in vitro approaches, we show that the presence of SM in model myelin membranes leads to a significant inhibition of the hydrolytic activity of HDP-2, decreased intermembrane phospholipid exchange, and reduced phospholipid polymorphism. Using AutoDock software, we show that the NH group of the sphingosine backbone of SM binds to Tyr22(C=O) of HDP-2 via a hydrogen bond which keeps only the polar head of SM inside the HDP-2's active center and positions the sn-2 acyl ester bond away from the active center, thus making it unlikely to hydrolyze the alkyl chains at the sn-2 position. This observation strongly suggests that SM inhibits the catalytic activity of HDP-2 by blocking access to other phospholipids to the active center of the enzyme. Should this observation be verified in further studies, it would offer a tantalizing opportunity for developing effective pharmaceuticals to stop the demyelination of nerve fibers by aberrant PLAs with overt activity - as observed in brain degenerative diseases - by inhibiting SM hydrolysis and/or facilitating SM synthesis in the myelin sheath membrane.

Chaudary AS, Guo Y, Utkin YN, Barancheshmeh M, Dagda RK, Gasanoff ES

IBCH: 11570
Ссылка на статью в журнале: https://doi.org/10.1007/s00232-024-00327-y
Кол-во цитирований на 09.2026: 7
Данные статьи проверены модераторами 2024-11-08

Список научных проектов, где отмечена публикация

  1. Пептидные и белковые соединения на основе структур змеиных токсинов как перспективные средства для коррекции патологий сердечно-сосудистой системы (6 Января 2024 года — 31 Декабря 2026 года). Уткин Ю.Н.. Грант, РНФ.